As it deepens immunology bets, Sanofi inks small molecule pact with Belharra

Belharra Therapeutics is riding the waves of Sanofi’s bid to become an “immunology powerhouse.

The California biotech — whose name derives from a famous surf break in France’s Basque region — will get $40 million in upfront and near-term payments, and up to almost $700 million down the line across R&D and commercial milestones, the companies said Tuesday morning.

Belharra is applying its non-covalent chemoproteomics platform to find and confirm hits against immunology targets selected by Sanofi. The companies did not disclose the number or the type of targets, except for saying they’ll look at ones considered “undruggable,” according to a statement from Sanofi’s global head of I&I research John Bertin.

The deal is Belharra’s second pharma collaboration, which follows a large pact with Genentech that covers four therapeutic areas.

Jeff Jonker

Sanofi has been aware of the Belharra…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks